MVM Life Science Partners

About

Portfolio · 3

OSSIO

Intelligent Bone Implant Technology

2 rounds $66.1M committed Latest: 2024-12

BioProtect

Developer of a biodegradable balloon implant for prostate cancer radiation therapy.

Led ★ 1 round $28.0M committed Latest: 2023-09

Cheetah Medical

Noninvasive Fluid Management Technologies

4 rounds $75.1M committed Latest: 2017-09

Investment activity

1 portfolio exit on record.

Funds · 1

• MVM VI — $500M Nov 2022

Q&A

What is MVM Life Science Partners' primary investment focus?

MVM Life Science Partners specializes in high-growth healthcare and life sciences companies, including medical technology, pharmaceuticals, diagnostics, and digital health.

When was MVM Life Science Partners founded?

MVM Life Science Partners was founded in 1997.

What is MVM Life Science Partners' most recent fund?

MVM Life Science Partners closed its MVM VI fund in November 2022, raising $500 million.

Can you name a notable exit for MVM Life Science Partners?

In September 2019, MVM Life Science Partners saw Cheetah Medical acquired by Baxter International for $230 million.

Which investment stages does MVM Life Science Partners typically participate in?

MVM Life Science Partners typically invests in B, C, and D rounds.

Which portfolio companies are highlighted for MVM Life Science Partners?

MVM Life Science Partners' portfolio includes BioProtect, which develops biodegradable balloons for radiation therapy, and OSSIO, focused on intelligent bone implant technology.

Where are MVM Life Science Partners' main offices located?

MVM Life Science Partners has offices in Boston, London, and the San Francisco Bay Area.

Who is a founding partner at MVM Life Science Partners?

Stephen Reeders is a founding partner at MVM Life Science Partners.